SmallCapReview.com is a leading small cap stock information site since 1999, to register for the free SmallCapReview newsletter visit http://www.smallcapreview.com.
AEterna Zentaris (Nasdaq: AEZS) Trading at $2.38, Up $0.69. Today announced that it presented results supporting the evaluation of its targeted cytotoxic peptide conjugate compound, AEZS-108, in prostate cancer. The presentation was made during yesterday's poster session at the American Society of Clinical Oncology Annual Meeting, being held through June 2, 2009 at the Orange County Convention Center in Orlando, Florida.
LHRH receptor expression was demonstrated in more than 95% of 130 prostate cancer specimens analyzed, irrespective of origin or patients' prior hormonal treatment. In all groups, the majority of specimens showed moderate to strong receptor expression. Statistically, strong receptor expression correlated with higher pathologic tumor stage and shorter overall survival.
What They Do: AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization.
Celldex Therapeutics (Nasdaq: CLDX) Trading at $12.02, Up $2.99. Today announced that promising clinical data from two Phase 1 studies of CDX-1307 were presented at the 45th Annual Meeting of the American Society of Clinical Oncology in Orlando, Florida. CDX-1307 is a dendritic cell targeted immunotherapy designed to stimulate an immune response against hCG Beta, a target antigen frequently expressed in epithelial tumors.
The comprehensive Phase 1 studies include over 70 patients and were designed to investigate the safety and immunogenicity of CDX-1307 using different routes of administration and in combination with immunostimulants, including GM-CSF and toll-like receptor agonists. CDX-1307 was well tolerated with no dose limiting toxicity to date. Robust immune responses were generated, and 7 patients with breast, colorectal and pancreatic cancers experienced disease stabilization for 2.2+ to 6.5+ months.
What They Do: Celldex Therapeutics is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases.
Merge Healthcare (Nasdaq: MRGE) and etrials Worldwide (Nasdaq: ETWC) $1.67, Up $0.40. Today announced that they have reached a definitive agreement for the acquisition of etrials by Merge. The combined organization will provide clinical trial sponsors and contract research organizations comprehensive and configurable solutions that include both critical imaging technologies and proven eClinical capabilities.
The Merge tender offer, which consists of a mix of $0.80 in cash and 0.3448 shares of Merge common stock for each share of etrials common stock, represents an aggregate value of $1.70 per share, calculated using the $2.610, 20-day volume-weighted average price of Merge common stock as of the close of market on May 26, 2009, which was the last trading day before Merge made this offer to etrials.
What They Do: Headquartered near North Carolina's Research Triangle Park, etrials Worldwide, Inc. (NASDAQ: ETWC), is a leading provider of eClinical software and services to pharmaceutical, biotechnology, and medical device companies, as well as contract research organizations, offering adaptive, Web-based tools that work together to coordinate data capture, logistics, patient interaction and trial management - turning data into intelligence and shortening the pathway to an actionable study endpoint. etrials is one of the few top-tier solution providers that offers electronic data capture, interactive voice and Web response and electronic patient diaries, as part of a flexible and integrated software-as-a-service platform or as individual solutions to capture high quality data from multiple pivot points to enable real-time access for informed decision-making.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for news on small-cap stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register visit http://www.smallcapreview.com/.
